Healthcare fund RTW Biotech Opportunities (RTW) significantly outperformed its major biotech benchmarks in a ‘standout’ FY25. The trust delivered an impressive 35.7% net asset value (NAV) return. Additionally, its share price increased by 54.8%, narrowing the NAV discount from 22.8% at the start of 2025 to 12% by year-end. RTW Bio’s FY25 share price performance … Continue reading Discover how RTW Bio outperformed in 2025